RxDoctor Payments Data

David Lew, MD

Cardiovascular Disease · Leesburg, FLNPI 1861485757

Payments from drug & device makers

$90,215in general payments, 2019–2025

Across 565 payments — averaging $159.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$79K
  • Boston Scientific$2K
  • Medtronic$2K
  • W. L. Gore & Associates, Inc.$2K
  • Penumbra, Inc.$2K
  • Cardinal Health 200 LLC$502
  • plus $3K from 32 others

What the payments were for

  • Grants$660%
  • Travel & lodging$1,1181%
  • Food & beverage$10,41812%
  • Education$140%
  • Gifts$1690%
  • Other$78,43187%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$90,215 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$1,940,468
Medicare patients
693
Services billed
20,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban268$349,298
EntrestoSacubitril/Valsartan88$131,169
Repatha SureclickEvolocumab101$102,094
XareltoRivaroxaban71$98,456
BrilintaTicagrelor20$21,176
JardianceEmpagliflozin15$16,053
ClopidogrelClopidogrel Bisulfate1,031$15,077
Repatha SyringeEvolocumab11$14,557
Metoprolol Succinate281$4,912
Atorvastatin Calcium302$3,490
Nebivolol Hcl27$2,466
Rosuvastatin Calcium130$2,193
Metoprolol Tartrate248$2,105
Isosorbide Mononitrate ErIsosorbide Mononitrate125$1,902
Ranolazine ErRanolazine16$1,844

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$203$349,298268 claims
NovartisEntresto$13$131,16988 claims
Johnson & JohnsonXarelto$15$98,45671 claims
AstraZenecaBrilinta$42$21,17620 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Leesburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →